Efinopegdutide
InvestigationalGLP-1/glucagon dual agonist
Also known as: MK-6024
Early evidence, mostly unproven in humans
- Regulatory standing. In clinical trials, not yet approved
- Limited human data. Some human data exists, not conclusive
- Registered human trials. 7 registered studies on ClinicalTrials.gov, most advanced Phase 2
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Efinopegdutide, also known as MK-6024, is an investigational long-acting peptide that activates both the GLP-1 receptor and the glucagon receptor. It is thought to act by combining GLP-1 effects on appetite and blood sugar with glucagon effects on liver fat metabolism and energy use. It is being developed by Merck mainly for metabolic dysfunction-associated liver disease (MASH/NASH).
What the evidence shows
Efinopegdutide is not FDA-approved. There are about seven registered human trials, with Phase 2 as the most advanced, and early studies reported reductions in liver fat, but larger and longer trials are needed to establish effects on liver outcomes and long-term safety.
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity.
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.